Special issue of the Journal of Neuromuscular Diseases is devoted to the Treatabolome, designed to shorten diagnosis-to-treatment time for patients with rare diseases

In 2019, as part of the European Solve-RD project, Hanns Lochmüller, Gisèle Bonne and Rachel Thompson launched the Treatabolome, an initiative designed to extract details of effective treatments for rare diseases from the scientific literature and make them accessible through an online database that aims to allow patients to receive the right treatment for their condition as soon as they receive a genetic diagnosis.

The process of extracting reliable treatment information from scientific publications begins with a systematic review of the literature for each disease area to ensure that all the published information is captured. The Lochmüller Lab’s original systematic review of congenital myasthenic syndromes provided a comprehensive overview of the treatments available for these rare but often highly treatable diseases, which are one of our lab’s main focus areas.

This month, an open-access special issue of the Journal of Neuromuscular Diseases dedicated to the Treatabolome has been published. It includes six systematic reviews contributed by experts on rare neurological disorders, summarising the literature on each disease group and linking treatments with genotype and causative variants. Thanks to the team at CNAG in Barcelona behind the RD-Connect Genome-Phenome Analysis Platform, the data is also being transformed into an online database to be launched later this summer, which is intended to reduce treatment delays for patients with rare diseases by directly linking diagnosis and treatment information.

The special issue also includes a systematic review on the metabolic myopathies from our lab with Alex Manta, Sally Spendiff, Hanns Lochmüller and Rachel Thompson as co-authors.

You can find Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’  here.

Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’.
Manta A, Spendiff S, Lochmüller H, Thompson R.
J Neuromuscul Dis. 2021;8(3):401-417.
doi: 10.3233/JND-200621.
PMID: 33720849

 

Access the special issue of the Journal of Neuromuscular Diseases here.

Read the press release about the Treatabolome special issue here.

1by1treatabolome

Read next...

We are hiring a new clinical research coordinator!

Lochmüller Research Group Hiring Clinical Trial Coordinator

Due to recent funding success and expansion of our clinical trials team we have a need for a highly motivated Research Coordinator that will assist...
First participant screened in global CMS natural history study

The Ottawa Neuromuscular Centre screens first participant in the world for a multinational congenital myasthenic syndrome natural history study

The neuromuscular centre at The Ottawa Hospital is excited to announce that we are the first site globally to screen a participant for the multinational...
Copy of Lochmuller Lab - PhD opportunity (LLab)

Lochmüller Lab seeking PhD student

The Lochmüller Research Group are seeking a highly motivated PhD student to join our team at the Childrens Hospital of Eastern Ontario Research Institute (CHEO...
New Publication - Leading global expert in DMD and bone health Dr. Leanne Ward publishes systematic review and grading of evidence for biphosphonate therapy in glucocorticoid-treated patients with Duchenne Muscular Dystrophy in Neurology, with Dr. Hanns Lochmüller as a co-author.

New Publication: Bisphosphonates in Glucocorticoid-Treated Patients with Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence

Leading global expert in Duchenne Muscular Dystrophy (DMD) and bone health Dr. Leanne Ward publishes systematic review and grading of evidence for bisphosphonate therapy in...
text reding new clinical trial opportunities

New Clinical Trial Opportunities for Children and Adults in Ottawa

Our clinical research team is excited to share five new clinical trials activated across both pediatric and adult sites in Ottawa, CHEO and TOH. We...
Dr. Andreas Roos receiving award on WMS 2023 stage, with text reading Congratulaions Dr. Andreas Roos, WMS President's Prize for Emerging Myologist of the Year 2023.

Dr. Andreas Roos wins Emerging Myologist of the Year Prize at WMS 2023

We are excited to congratulate Dr. Andreas Roos on winning the World Muscle Society’s (WMS) President’s Prize for Emerging Myologist of the Year!   This award...